Xcout Intel
Meta Pharmaceuticals competitors & alternatives
The 12 closest competitors and alternatives to Meta Pharmaceuticals among drug discovery companies — ranked by similarity to what Meta Pharmaceuticals actually does, not by market-cap band.
Subscribe to see Meta Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Meta Pharmaceuticals
META Pharmaceuticals Inc. is a pioneering biotechnology company focusing on immuno-metabolism and gastrointestinal therapeutics within immunology, operating research efforts connected to JLABS in Shanghai.
Meta Pharmaceuticals at a glance
Meta Pharmaceuticals is a drug discovery company. It has raised at least $15M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round closed in February 2025. Xcout tracks 8 named people at Meta Pharmaceuticals, including Guoxing Wei (天图资本合伙人).
Meta Pharmaceuticals leadership
- Guoxing Wei天图资本合伙人
- Shuhao Wen晶泰科技创始人/董事长
- Tianxiang Tang执行合伙人/融资负责人
- Yide Jiang晶泰科技首席策略官 & IMO创投合伙人
- Anjin Xianyu联合创始人/首席技术官
- Ke Xu创始人/首席执行官
2 more named people on record for Meta Pharmaceuticals, with roles, board committees and tenure — see the full roster →
Meta Pharmaceuticals funding rounds
At least $15M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | Undisclosed | 4 named | |
| — | $15M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Meta Pharmaceuticals competitors
Ranked by semantic similarity — how close each company is to Meta Pharmaceuticals by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar drug discovery company
Caldera Therapeutics, Inc. is a Cambridge, Massachusetts-based clinical-stage biotechnology company focused on treatments such as a bispecific inflammatory bowel disease (IBD) asset.
Similar drug discovery company
Coultreon Biopharma is a clinical-stage biotechnology company headquartered in Leuven, Belgium, focused on developing next-generation precision medicines for immunology and autoimmune diseases. Backed by substantial venture funding, the company advances innovative therapies.
Similar drug discovery company
COUR Pharmaceuticals is a clinical-stage biotechnology company headquartered in Evanston, Illinois, founded in 2015. The firm focuses on reprogramming the immune system to develop novel treatments for autoimmune diseases.
Similar drug discovery company
Automera is an early-stage biotechnology research company headquartered in Singapore. The company focuses on the development of novel therapeutics through autophagy-based targeted protein degradation.
Similar drug discovery company
Vivacta Biotechnology is a biopharmaceutical company headquartered in Shanghai, China, specializing in innovative biotechnology research. The company is focused on developing in vivo CAR-T therapies utilizing a targeted delivery system.
Similar drug discovery company
Metsera, Inc. is a clinical-stage biopharmaceutical company traded on the NASDAQ under the symbol MTSR, with its headquarters located in New York, New York, focusing on next-generation obesity and metabolic portfolios.
Similar drug discovery company
Promise Bio is a biotechnology research startup transforming immune-mediated disease treatment with advanced precision therapies. Headquartered in Tel Aviv, Israel, the company emerged from stealth following a seed investment.
Similar drug discovery company
NXI Therapeutics AG is a biotech company based in Basel, Switzerland, focused on researching and developing selective immunosuppressive drugs and immunotherapies for autoimmune diseases and transplantation.
Biopharmaceuticals
CORXEL Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world. The company is a leading biotech firm with operations in the United States and China.
Biopharmaceutical
Createrna, Inc. is an innovative biopharmaceutical company dedicated to the discovery and development of treatments for immunology, respiratory, and cardiovascular diseases. The company focuses its research pipeline on addressing complex chronic conditions through targeted therapeutic approaches. Their portfolio highlights early-stage pharmaceutical developments in specialized medical fields.
Biopharmaceuticals
Alba Therapeutics Corp. was a U.S. biopharmaceutical company focused on therapies for gastrointestinal and autoimmune disorders. Its lead program was larazotide acetate, an investigational zonulin antagonist intended to help patients with celiac disease by reducing intestinal permeability.
Biopharmaceuticals
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Meta Pharmaceuticals and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Meta Pharmaceuticalsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →